nach oben

PharmacoEconomics

Erschienen in:

01.10.2001 | Review Article

Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease

Impact of Motor Fluctuations and Dyskinesias

verfasst von: Dr Richard C. Dodel, Karin Berger, Wolfgang H. Oertel

Erschienen in: PharmacoEconomics | Ausgabe 10/2001

Einloggen, um Zugang zu erhalten

Abstract

Idiopathic Parkinson’s disease (PD) is a common chronic progressive neurodegenerative disorder associated with the progressive loss of dopaminergic neurons in the substantia nigra. The natural course of the disease may lead to severe disability despite a variety of pharmacological and surgical treatment options. Levodopa is still the most effective symptomatic treatment for PD; however, long term use can cause a number of adverse effects including motor complications, nausea and vomiting, postural hypotension and changes in mental status.

The onset of motor complications marks a crucial point in the management of PD. They may present as changes between akinetic and mobile phases (motor fluctuations) or as abnormal involuntary movements (dyskinesias). After levodopa treatment for 3 to 5 years, motor complications occur in approximately 50% of patients, and after 10 years in >80% of patients. Treatment options have recently expanded as new drugs have been licensed and surgical procedures refined. Patients with motor complications present a demanding task in disease management, and often multiple drugs and high dosages are necessary to achieve only suboptimal control, resulting in increased healthcare utilisation.

Costs increase considerably in patients with motor fluctuations and dyskinesias compared with patients without these symptoms. In a French study, 6-month direct medical costs per patient increased from 1648 euros (EUR) to EUR3028 in patients without and with motor fluctuations, respectively. In a recent French study a significant difference in monthly direct medical costs was found in patients with and without dyskinesias (EUR560 vs 170). Unfortunately, no data are available on the effect of motor complications on indirect costs. Several studies have shown that health-related quality of life (HR-QOL) is reduced when motor fluctuations occur. This may also be true of dyskinesias, but because of the limited number of studies a definite conclusion is not yet possible.

Recently, surgical treatment options have been used to deal with advanced PD and late stage complications. Although their effect on motor complications and HR-QOL is well documented, they result in increased costs (total medical cost: EUR28920) compared with drug treatment alone and are increasingly restricted by healthcare providers.

The purpose of this article is to review the available data from pharmacotherapeutic, surgical and economic studies on HR-QOL and healthcare expenditure in patients with PD, with a major focus on the impact of motor fluctuations and dyskinesias.

The descriptions of acute, fatal fulminant hepatitis and potentially fatal neurological reactions, in association with tolcapone, led to the suspension of its marketing authorisation in the European Community and Canada in 1998. In many countries, the use of tolcapone is now restricted to patients who are not responding satisfactorily to other therapies.

Despite their use in clinical studies, some of theHR-QOL scales are unsuitable for frail elderly people to complete. The SIP is extremely long and complicated. Also there has been concerns raised about the utility of the SF-36 measure when employed with elderly populations.

Marsden CD. Parkinson’s disease. Lancet 1990; 335: 948–52PubMedCrossRef

Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16: 278–82PubMedCrossRef

Sutcliffe RL, Meara JR. Parkinson’s disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995; 92: 443–50PubMedCrossRef

Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19 Suppl.: 253–64

Maier-Hoehn MA. The natural history of Parkinson’s disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10: 331–9

Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42PubMedCrossRef

Hughes AJ, Daniel SE, Kilford L, et al. The accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4PubMedCrossRef

Rinne UK. Problems associated with long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 1983; 95 Suppl.: 19–26CrossRef

Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson’s disease. Carnforth: Parthenon Publishing Company, 1992: 89–112

10.

Weiner WJ. The initial treatment of Parkinson’s disease should begin with levodopa. Mov Disord 1999; 14: 716–24PubMedCrossRef

11.

Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord 1999; 14: 725–30PubMedCrossRef

12.

Grandas F, Galiano M, Tabernero C. Risk factors for levodopainduced dyskinesias in Parkinson’s disease. J Neurol 1999; 246: 1127–33PubMedCrossRef

13.

Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson’s disease. Neurology 1991; 41: 622–9PubMedCrossRef

14.

Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson’s disease: a longitudinal study over 6 years. Mov Disord 1999; 14: 605–11PubMedCrossRef

15.

Denny AP, Behari M. Motor fluctuations in Parkinson’s disease. J Neurol Sci 1999; 165: 18–23PubMedCrossRef

16.

Jenkinson C, Fitzpatrick R, Peto V. Health-related quality-of-life measurement in patients with Parkinson’s disease. Pharmacoeconomics 1999; 15: 157–65PubMedCrossRef

17.

LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999; 16: 59–69PubMedCrossRef

18.

Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299–312PubMedCrossRef

19.

Maurel F, Lilliu H, LePen C. Le coût socio-économique des dyskinésies associées au traitement par la L-Dopa chez des patients atteints de maladie de Parkinnson. Rev Neurol 2001; 157: 507–14PubMed

20.

Quinn NP. Classification of fluctuations in patients with Parkinson’s disease. Neurology 1998; 51: S25–9PubMedCrossRef

21.

Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, et al., editors. Neurological disorders: course and treatment. San Diego (CA): Academic Press, 1996: 715–72

22.

Marsden CD, Parkes JD, Quinn NP. Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 96–122

23.

Vidailhet M, Bonnet AM, Marconi R, et al. The phenomenology of L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 1999; 14 Suppl. 1: 13–8PubMed

24.

Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S2–S11PubMed

25.

Poewe WH, Lees AJ, Stem GM. Dystonia in Parkinson’s disease. Ann Neurol 1988; 23: 73–8PubMedCrossRef

26.

Nutt JG. L-Dopa induced dyskinesias: review, observations, and speculations. Neurology 1990; 40: 340–5PubMedCrossRef

27.

Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov Disord 1994; 9: 2–12PubMedCrossRef

28.

Quinn NP. Parkinson’s disease dyskinesias. Neurology 1994; 44: 1187–8PubMedCrossRef

29.

Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson’s disease. Neurology 1993; 43: 1459–64PubMedCrossRef

30.

Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease I. New York (NY): Macmillan, 1987: 153–63

31.

Alarcon F, Cevallos N, Lees AJ. Does combined levodopa and bromocriptine therapy in Parkinson’s disease prevent late motor complications? Eur J Neurol 1998; 5: 255–63PubMedCrossRef

32.

Cedarbaum JM, Silvestri M. Methods for assessing motor fluctuations in conducting clinical trials of antiparkinson agents. In: Clifford-Rose F, editor. Parkinson’s disease and the problem of clinical trials. London: Smith-Gordon, 1992: 75–85

33.

Defer GL, Widner H, Marie RM, et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 1999; 14: 572–84PubMedCrossRef

34.

Goetz CG. Rating scales for dyskinesias in Parkinson’s disease. Mov Disord 1999; 14 Suppl. 1: 48–53PubMed

35.

Widner H, Defer G. Dyskinesias assessment: from CAPIT to CAPSIT. Mov Disord 1999; 14 Suppl. 1: 60–6PubMed

36.

Nutt J. A unified dyskinesias rating scale for L-dopa-induced dyskinesias? Mov Disord 1999; 14 Suppl. 1: 74PubMed

37.

Hoff JI, van Hilten BJ, Roos RA. A review of the assessment of dyskinesias. Mov Disord 1999; 14: 737–43PubMedCrossRef

38.

Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S70–8PubMed

39.

Filion M. Physiologic basis of dyskinesia. Ann Neurol 2000; 47 Suppl. 1: S35–40PubMed

40.

Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol 2000; 47 Suppl. 1: S22–32PubMed

41.

Nutt JG. Pharmacodynamics of levodopa in Parkinson’s disease. Clin Exp Pharmacol Physiol 1995; 22: 837–40PubMedCrossRef

42.

Nutt JG. Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol 2000; 47 Suppl. 1: S160–4PubMed

43.

Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992; 10: 487–509PubMed

44.

Nutt JG. Effect of long-term therapy on the pharmacodynamics of levodopa. Arch Neurol 1992; 49: 1123–30PubMedCrossRef

45.

Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci 2000; 23: S109–15PubMedCrossRef

46.

Olanow W, Schapira AH, Rascol O. Continuous dopaminereceptor stimulation in early Parkinson’s disease. Trends Neurosci 2000; 23 Suppl.: S117–26PubMedCrossRef

47.

Obeso J, Olanow CW, Jenner P, et al. Levodopa-induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S1–S203

48.

Olanow CW, Obeso J, Nutt JG, et al. Basal ganglia, Parkinson’s disease and levodopa therapy. Trends Neuroci 2000; 23 Suppl.: S1–126CrossRef

49.

Rascol O. L-Dopa induced peak dose dyskinesias in patients with Parkinson’s disease: a clinical pharmacologic approach. Mov Disord 1999; 14 Suppl.: 19–32PubMed

50.

Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56 Suppl. 5: S1–88PubMedCrossRef

51.

Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997; 20: 95–115PubMedCrossRef

52.

Melamed E, Zoldan J, Galili-Mosberg R, et al. Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa. J Neural Transm 1999; 56 Suppl.: 173–83CrossRef

53.

Colosimo C, De Michele M. Motor fluctuations in Parkinson’s disease: pathophysiology and treatment. Eur J Neurol 1999; 6: 1–21PubMedCrossRef

54.

Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S179–88PubMed

55.

Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias [discussion S176-8]. Ann Neurol 2000; 47 Suppl. 1: S167–76PubMed

56.

Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the ‘wearing off’ phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology 1998; 50 Suppl. 5: S46–53PubMedCrossRef

57.

Holm KJ, Spencer CM. Entacapone: a review of its use in Parkinson’s disease. Drugs 1999; 58: 159–77PubMedCrossRef

58.

Arnold G, Kupsch A. Inhibition of catechol-O-methyltransferase: optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone. Nervenarzt 2000; 71: 78–83PubMedCrossRef

59.

Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91PubMedCrossRef

60.

Oertel WH. Pergolide vs. L-Dopa (Pelmopet) [abstract]. Mov Disord 2000; 15 Suppl. 3: 24

61.

Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23–30PubMedCrossRef

62.

Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PDStudy. Parkinson Study Group. Clin Neuropharmacol 2000; 23: 34–44CrossRef

63.

Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383–6PubMedCrossRef

64.

Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson’s disease. Curr Opin Neurol 2000; 13: 431–6PubMedCrossRef

65.

Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998; 65: 709–16PubMedCrossRef

66.

Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998; 55 Suppl. 1: 1–9PubMedCrossRef

67.

Starr PA, Vitek JL, Bakay RA. Ablative surgery and deep brain stimulation for Parkinson’s disease [discussion 1013-5]. Neurosurgery 1998; 43: 989–1013PubMedCrossRef

68.

de Bie RM, de Haan RJ, Nijssen PC, et al. Unilateral pallidotomy in Parkinson’s disease: a randomised, single-blind, multicentre trial. Lancet 1999; 354: 1665–9PubMedCrossRef

69.

Lindvall O. Update on fetal transplantation: the Swedish experience. Mov Disord 1998; 13 Suppl. 1: 83–7PubMed

70.

Benabid AL, Benazzouz A, Hoffmann D, et al. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord 1998; 13 Suppl. 3: 119–25PubMed

71.

Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 1998; 339: 1105–11PubMedCrossRef

72.

Limousin-Dowsey P, Pollak P, Van Blercom N, et al. Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson’s disease. J Neurol 1999; 246 Suppl. 2: 1142–5

73.

Volkmann J, Sturm V, Weiss P, et al. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson’s disease. Ann Neurol 1998; 44: 953–61PubMedCrossRef

74.

Honey C, Gross RE, Lozano AM. New developments in the surgery for Parkinson’s disease. Can J Neurol Sci 1999; 26 Suppl. 2: S45–52PubMed

75.

Krack P, Limousin P, Benabid AL, et al. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson’s disease [letter]. Lancet 1997; 350: 1676PubMedCrossRef

76.

Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease. Brain 1998; 121: 451–7PubMedCrossRef

77.

Ghika J, Villemure JG, Fankhauser H, et al. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson’s disease with severe motor fluctuations: a 2-year follow-up review. J Neurosurg 1998; 89: 713–8PubMedCrossRef

78.

Iacopino DG, Lucerna S, Giller CA, et al. Pallidotomy improves quality of life in selected parkinsonian patients: an Italian report. Funct Neurol 1998; 13: 105–15PubMed

79.

Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalmic nucleaus stimulation in advanced PD. Neurology 2001; 56: 548–51PubMedCrossRef

80.

Houeto JL, Damier P, Bejjani PB, et al. Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. Arch Neurol 2000; 57: 461–5PubMedCrossRef

81.

Krack P, Pollak P, Limousin P, et al. From off-period dystonia to peak-dose chorea: the clinical spectrum of varying subthalamic nucleus activity. Brain 1999; 122: 1133–46PubMedCrossRef

82.

Moro E, Scerrati M, Romito LM, et al. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology 1999; 53: 85–90PubMedCrossRef

83.

Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease. Neurology 1998; 51: 850–5PubMedCrossRef

84.

Vingerhoets G, Lannoo E, van der Linden C, et al. Changes in quality of life following unilateral pallidal stimulation in Parkinson’s disease. J Psychosom Res 1999; 46: 247–55PubMedCrossRef

85.

Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson’s disease: a consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998; 121: 659–75PubMedCrossRef

86.

Straits-Troster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn 2000; 42: 399–416PubMedCrossRef

87.

Laitinen LV, Bergenheim AT, Hariz MI. Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact Funct Neurosurg 1992; 58: 14–21PubMedCrossRef

88.

Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 1995; 346: 1383–7PubMedCrossRef

89.

Bejjani B, Damier P, Arnulf I, et al. Pallidal stimulation for Parkinson’s disease: two targets? Neurology 1997; 49: 1564–9PubMedCrossRef

90.

Krack P, Pollak P, Limousin P, et al. Opposite motor effects of pallidal stimulation in Parkinson’s disease. Ann Neurol 1998; 43: 180–92PubMedCrossRef

91.

Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol 2000; 57: 983–8PubMedCrossRef

92.

Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft. Brain 1999; 122: 1121–32PubMedCrossRef

93.

Lindvall O, Hagell P. Cell therapy and transplantation in Parkinson’s disease. Clin Chem Lab Med 2001 Apr; 39 (4): 356–61PubMedCrossRef

94.

Freed CR, Green PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001; 344: 710–9PubMedCrossRef

95.

Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson’s disease: stop or go? Nat Rev Neurosci 2001; 2: 365–9PubMedCrossRef

96.

Naderson RT, Aaronson NK, McBee WL. A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 1996; 10: 336–55CrossRef

97.

Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40: 355–66PubMedCrossRef

98.

Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23–7PubMedCrossRef

99.

Longstreth Jr WT, Nelson L, Linde M, et al. Utility of the sickness impact profile in Parkinson’s disease. J Geriatr Psychiatry Neurol 1992; 5: 142–8PubMed

100.

Hobson JP, Meara RJ. Is the SF-36 health survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson’s disease. Qual Life Res 1997; 6: 213–6PubMedCrossRef

101.

McHorney CA. Measuring and monitoring general health status in elderly persons: practical and methodological issues in using the SF-36 Health Survey. Gerontologist 1996; 36: 571–83PubMedCrossRef

102.

Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D — a generic quality of life measure — is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000; 69: 67–73PubMedCrossRef

103.

Findley L, Peto V, Pugner K, et al. The impact of Parkinson’s disease on quality of life: results of a research survey in the U.K. [abstract]. Mov Disord 2000; 15 Suppl. 3: 179

104.

Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med 2001; 33: 337–43PubMedCrossRef

105.

Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33: 328–36PubMedCrossRef

106.

Damiano AM, Snyder C, Strausser B, et al. A review of health-related quality-of-life concepts and measures for Parkinson’s disease. Qual Life Res 1999; 8: 235–43PubMedCrossRef

107.

Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997; 26: 353–7PubMedCrossRef

108.

Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 Suppl. 1: S10–4PubMedCrossRef

109.

Berger K, Broll S, Winkelmann J, et al. Untersuchung zur Reliabilität der deutschen Version des PDQ-39: Ein krankheitsspezifischer Fragebogen zur Erfassung der Lebensqualität von Parkinson-Patienten. Akt Neurologie 1999; 26: 180–4CrossRef

110.

Bushnell DM, Martin ML. Quality of life and Parkinson’s disease: translation and validation of the US Parkinson’s Disease Questionnaire (PDQ-39). Qual Life Res 1999; 8: 345–50PubMedCrossRef

111.

Martinez Martin P, Frades B, Jimenez Jimenez FJ, et al. The PDQ-39 Spanish version: reliability and correlation with the short-form health survey (SF-36). Neurologia 1999; 14: 159–63PubMed

112.

Martinez-Martin P, Frades Payo B. Quality of life in Parkinson’s disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol 1998; 245 Suppl. 1: S34–8PubMedCrossRef

113.

de Boer AG, Wijker W, Speelman JD, et al. Quality of life in patients with Parkinson’s disease: development of a questionnaire. J Neurol Neurosurg Psychol 1996; 61: 70–4CrossRef

114.

Hobson P, Holden A, Meara J. Measuring the impact of Parkinson’s disease with the Parkinson’s Disease Quality of Life questionnaire. Age Ageing 1999; 28: 341–6PubMedCrossRef

115.

Martinez-Martin P, Frades Payo B, Fontan Tirado C, et al. Assessing quality of life in Parkinson’s disease using the PDQ-39. A pilot study. Neurologia 1997; 12: 56–60PubMedCrossRef

116.

Ueda S, Ando N, Nakae K, et al. The simple comprehensive evaluation of quality of life. In: Ueda S, editor. Annual Report of the Research committee of SMON. Tokyo: Ministry of Health and Welfare of Japan, 1994: 273–5

117.

Gold DT, Boisture J, Shipp KM, et al. Paget’s disease of bone and quality of life. J Bone Miner Res 1996; 11: 1187–903

118.

Hogan T, Grimaldi R, Dingemanse J, et al. The Parkinson’s disease symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects. Park Rel Disord 1999; 5: 93–8CrossRef

119.

Calne S, Schulzer M, Mak E, et al. Validating a quality of life rating scale for idiopathic parkinson’s disease. Parkinson Rel Dis 1996; 2: 55–61CrossRef

120.

Rubenstein LM, Voelker MD, Chrischilles EA, et al. The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson’s disease research. Qual Life Res 1998; 7: 279–90PubMedCrossRef

121.

Peterman A, D’Antonio L, Zimmermann G. Measuring global quality of life in patients with Parkinson’s disease [abstract]. Mov Disord 1997; 12: 136

122.

Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–40PubMedCrossRef

123.

Glozman JM, Bicheva KG, Fedorova NV. Scale of quality of life of care-givers (SQLC). J Neurol 1998; 245 Suppl. 1: S39–41PubMedCrossRef

124.

Fitzpatrick R, Peto V, Jenkinson C, et al. Health-related quality of life in Parkinson’s disease: a study of outpatient clinic attenders. Mov Disord 1997; 12: 916–22PubMedCrossRef

125.

Lyons KE, Pahwa R, Tröster AI, et al. A comparison of Parkinson’s disease symptoms and self-reported functioning and well being. Park Rel Dis 1998; 3: 207–9CrossRef

126.

Jenkinson C, Peto V, Fitzpatrick R, et al. Self-reported functioning and well-being in patients with Parkinson’s disease: comparison of the short-form health survey (SF-36) and the Parkinson’s Disease Questionnaire (PDQ-39). Age Ageing 1995; 24: 505–9PubMedCrossRef

127.

Koplas PA, Gans HB, Wisely MP, et al. Quality of life and Parkinson’s disease. J Gerontol A Biol Sci Med Sci 1999; 54: M197–202PubMedCrossRef

128.

Karlsen KH, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66: 431–5PubMedCrossRef

129.

Karlsen KH, Tandberg E, Arsland D, et al. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000; 69: 584–9PubMedCrossRef

130.

Findley L. Investigating factors which may influence quality of life in Parkinson’s disease [abstract]. Parkinsonism Rel Dis 1999; 5 Suppl.: 146

131.

Kuopio AM, Marttila RJ, Helenius H, et al. The quality of life in Parkinson’s disease. Mov Disord 2000; 15: 216–23PubMedCrossRef

132.

Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000; 69: 308–12PubMedCrossRef

133.

Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112–8PubMedCrossRef

134.

Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000; 57: 953–62PubMed

135.

Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study. Brain 2000; 123: 2297–305PubMedCrossRef

136.

Keränen T, Kaakola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of Parkinson’s disease: a health economic study of PD patients in Finland. Parkinsonism Rel Dis 2001; 7 Suppl. S105

137.

Pechevis M, Clarke C, Vieregge P, et al. Direct and indirect costs of Parkinson’s disease and L-Dopa-induced dyskinesia: a prospective European study. Parkinsonism Rel Dis 2001; 7 Suppl.: S106

138.

Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of life. Qual Life Res 2000; 9: 87–100PubMedCrossRef

139.

Rosser R. A health index and output measure. In: Walker SR, Rosser RM, editors. Quality of life: assessment and application. Lancaster: MTP Press Ltd, 1988: 133–60

140.

Torrance GW. Measurement of health status utilities for economic appraisal. J Health Econ 1986; 5: 1–30PubMedCrossRef

141.

Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Mov Disord 1998; 13: 20–8PubMedCrossRef

142.

Singer E. The effect of treatment with levodopa on Parkinson patients’ social functioning and outlook on life. J Chronic Dis 1974; 27: 581–94PubMedCrossRef

143.

Martinez-Martin P, Grandas F, Linazasoro G, et al. Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. Neurologia 1999; 14: 338–43PubMed

144.

Adler CH, Singer C, O’Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998; 55: 1089–95PubMedCrossRef

145.

D’Antonio LL, Zimmerman GJ, Iacono RP. Changes in health related quality of life in patients with Parkinson’s disease with and without posteroventral pallidotomy. Acta Neurochir 2000; 142: 759–68CrossRef

146.

Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson’s disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 2000; 15: 230–7PubMedCrossRef

147.

Dodel RC, Spottke AE, Oertel WH. Quality of life and costs of neurosurgical procedures in the treatment of Parkinson’s disease. Akt Neurol 2000; 27: Suppl. 1: S61–9CrossRef

148.

Hagell P, Crabb L, Pogarell O, et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson’s disease. Mov Disord 2000; 15: 224–9PubMedCrossRef

149.

Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson’s disease. Mov Disord 1998; 13: 406–13PubMedCrossRef

150.

Dodel RC, Singer M, Kohne-Volland R, et al. Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs. Nervenarzt 1997; 68: 978–84PubMedCrossRef

151.

Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson’s disease on health status, health expenditures, and productivity: estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997; 12: 486–98PubMedCrossRef

152.

Ziegler M, Levy E. Approche économique du coût de traitement de la maladie de parkinson. Ann Psychiatr 1990; 54: 348–53

153.

Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics 1998; 14: 541–57PubMedCrossRef

154.

Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844–9PubMed

155.

Haycock J. Idiopathic Parkinson’s disease: the burden of illness. York: University of York, 1992

156.

Siderowf A, Holloway R, Mushlin A. Cost-effectiveness of pallidotomy and add-on medical therapy in advanced Parkinson’s disease [abstract]. Ann Neurol 1998; 44: 517

157.

Clarke CE, Zobkiw RM, Gullaksen E. Quality of life and care in Parkinson’s disease. Br J Clin Pract 1995; 49: 288–93PubMed

158.

Peto V, Fitzpatrick R, Jenkinson C. Self-reported health status and access to health services in a community sample with Parkinson’s disease. Disabil Rehabil 1997; 19: 97–103PubMedCrossRef

159.

MacMahon DG, Findley L, Holmes J, et al. The true economic impact of Parkinson’s disease: a research survey in the U.K. Mov Disord 2000; 15 Suppl. 3: 178–9

160.

Fukunaga H, Kasai T, Yoshidome H. Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson’s disease. Eur Neurol 1997; 38 Suppl. 2: 64–9PubMedCrossRef

161.

Dodel RC, Eggert KM, Oertel WH. Economical research on Parkinson’s disease: a review of the literature. Eur J Neurol 1999; 6 Suppl. 2: S3–S15

162.

Palmer C, Nuijten M, Schmier J, et al. The cost-effectiveness of treatment with entacapone for patients with Parkinson’s disease in the United States. Parkinsonism Rel Dis 2001; 7 Suppl.: S106

163.

Belouet C, Bonnichon P, Douard MC, et al. Elements for a cost/utility analysis of long term intravenous devices. Pathol Biol (Paris) 1999; 47: 282–7

164.

Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost-effectiveness analysis. Neurology 2001; 57: 663–71PubMedCrossRef

165.

Singer E. Social costs of Parkinson’s disease. J Chronic Dis 1973; 26: 243–54PubMedCrossRef

166.

Späte HF, Gemende G, Gemende I. Psychosocial aspects of the long-term care of parkinsonian patients [in German]. Psychiatr Neurol Med Psychol (Leipz) 1988; 40: 385–94

167.

Ellgring H, Seiler S, Perleth B, et al. Psychosocial aspects of Parkinson’s disease. Neurology 1993; 43: 641–4CrossRef

168.

Ellgring JH. Depression, psychosis, and dementia: impact on the family. Neurology 1999; 52 Suppl. 3: S17–S20PubMed

169.

Sutcliffe RL, Prior R, Mawby B, et al. Parkinson’s disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability. Acta Neurol Scand 1985; 72: 363–79PubMedCrossRef

170.

Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson’s disease in a Scottish city. BMJ 1986; 292: 534–6PubMedCrossRef

171.

Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 6: 135–45PubMed

172.

Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer’s disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221–4PubMed

173.

Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227–9PubMedCrossRef

174.

Reilly RF, Rabe JR. The valuation of health care intangible assets. Health Care Manage Rev 1997; 22: 55–64PubMed

175.

Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson’s disease [abstract]. Ann Neurol 1988; 24: 153CrossRef

Titel: Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease
Impact of Motor Fluctuations and Dyskinesias
verfasst von: Dr Richard C. Dodel
Karin Berger
Wolfgang H. Oertel
Publikationsdatum: 01.10.2001
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 10/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200119100-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2001

Which Antifungal Agent for Onychomycosis?

A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis

Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis

Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression

Barrett’s Oesophagus